首页> 外文期刊>Women’s health. >Low-molecular-weight heparin in women with repeated implantation failure.
【24h】

Low-molecular-weight heparin in women with repeated implantation failure.

机译:低分子量肝素在反复植入失败的女性中。

获取原文
获取原文并翻译 | 示例
           

摘要

Implantation failure is common in assisted reproduction techniques (ART). The role of low-molecular-weight heparin (LMWH) is a matter of debate as a potential factor to improve implantation. Aim: To evaluate the pregnancy rate in patients with or without heparin administration. Materials & methods: We performed a retrospective observational analysis of patients with at least two IVF/intracytoplasmic sperm injection cycles with implantation failure, screened for inherited thrombophilia and submitted to further ART cycles with or without administration of LMWH. A total of 265 patients fulfilled the enrollment criteria. Of these 149 (56%) were primary infertile and 116 (44%) were secondary infertile. Their mean age was 36.3 +/- 3.6 years. We analyzed basal FSH, smoking habit, gene variants for inherited thrombophilia (i.e., MTHFR C677T, prothrombin G202A10G and Factor V Leiden). The patients underwent 569 new ART cycles: 512 (90%) without and 57 (10%) with LMWH. Results: In total 105 clinical pregnancies were observed in 569 cycles (18.8%). The pregnancy rate was 17.19% (88/512) in patients not treated with LMWH and 29.52% (17/57) in the LMWH-treated group (p = 0.006). In women over 36 years of age the pregnancy rate was 15.53% (50/322) in nontreated versus 35.71% (10/28) in treated cycles (p = 0.007), while no difference was found in younger women. No statistical difference was found between the presence of inherited thrombophilia and pregnancy rate in treated and untreated cycles. Discussion: significantly higher pregnancy rate in patients with previous ART implantation failures was observed with LMWH. Our results confirm no relation among inherited thrombophilia and pregnancy rate in patients with previous IVF implantation failures. These findings should be confirmed by randomized controlled trials before use of LMWH for ART cycles is recommended.
机译:植入失败在辅助生殖技术(ART)中很常见。低分子量肝素(LMWH)的作用作为改善植入的潜在因素尚有争议。目的:评估使用或不使用肝素的患者的妊娠率。材料与方法:我们对至少两个体外受精/胞浆内精子注射失败且植入失败,遗传性血友病的患者进行了回顾性观察分析,并接受或不服用LMWH进行进一步的ART周期治疗。共有265位患者符合入组标准。在这149名(56%)为原发性不孕症中,有116名(44%)为继发性不孕症。他们的平均年龄为36.3 +/- 3.6岁。我们分析了基础FSH,吸烟习惯,遗传性血友病的基因变异(即MTHFR C677T,凝血酶原G202A10G和Factor V Leiden)。患者接受了569个新的ART周期:不使用LMWH的患者为512(90%),使用LMWH的患者为57(10%)。结果:在569个周期中共观察到105例临床妊娠(18.8%)。未接受LMWH治疗的患者的妊娠率为17.19%(88/512),而接受LMWH治疗的患者的妊娠率为29.52%(17/57)(p = 0.006)。在36岁以上的女性中,未接受治疗的妊娠率为15.53%(50/322),而接受治疗的妊娠率为35.71%(10/28)(p = 0.007),而年轻妇女则没有差异。在治疗和未治疗周期中,遗传性血友病的存在与妊娠率之间无统计学差异。讨论:LMWH观察到先前ART植入失败的患者的妊娠率显着提高。我们的结果证实,以前有试管婴儿植入失败的患者,遗传性血栓形成与妊娠率无关。在建议将LMWH用于ART周期之前,应通过随机对照试验确认这些发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号